

Special Issue

Molecular Research of Psychiatric Diseases

Message from the Guest Editor

The present Special Issue focuses on the molecular details of psychiatric diseases. Among other things, we are expecting results that can lead to the identification of novel diagnostic markers and drug targets, not only from animal but also from human studies. These data can serve as a basis for further translational and clinical studies. The topic of the issue will cover but is not limited to:

- Molecular background of psychiatric diseases;
- Anxiety disorder, PTSD, schizophrenia, Alzheimer's disease, autism spectrum disorder (ASD), depression;
- Role of neurotransmitters in neuropsychiatric diseases;
- Role of neuropeptides in neuropsychiatric diseases;
- Role of interactions of neuropeptides and neurotransmitters in neuropsychiatric diseases;
- Role of neuropeptides and their receptors in the treatment of neuropsychiatric diseases;
- Use of techniques such as RNAscope technology and transcriptomic analysis in psychiatric diseases;
- Behavioral effects of neurotransmitters in psychiatric diseases;
- Behavioral effects of neuropeptides in psychiatric diseases;
- Psychiatric diseases and homeostasis.

Guest Editor

Dr. Anita Kovács

Medical School, Institute of Physiology, University of Pécs, Szegedi Str. 12, P.O. Box 99, 7602 Pécs, Hungary

Deadline for manuscript submissions

closed (31 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/140368

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).